HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.

Powles T, Bhatia A, Burtness B, Kogawa T, Nishina T, Nakayama I, Fountzilas C, Castillo DR, McKean M, Meric-Bernstam F, Colombo N, Smithy JW, Fayette J, Chandra S, Sternberg DW, Jin F, Sullivan K, Yueh S, Clinthorne G, Aguilo AE, Kudchadkar R, Hayashi H

Open source

DOI: 10.1080/14796694.2025.2561539
Published: 2025 Oct
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2025.2561539,
  title = {HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.},
  author = {Powles T and Bhatia A and Burtness B and Kogawa T and Nishina T and Nakayama I and Fountzilas C and Castillo DR and McKean M and Meric-Bernstam F and Colombo N and Smithy JW and Fayette J and Chandra S and Sternberg DW and Jin F and Sullivan K and Yueh S and Clinthorne G and Aguilo AE and Kudchadkar R and Hayashi H},
  year = {2025},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2025.2561539},
  url = {https://doi.org/10.1080/14796694.2025.2561539}
}

RIS

TY  - JOUR
TI  - HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
AU  - Powles T
AU  - Bhatia A
AU  - Burtness B
AU  - Kogawa T
AU  - Nishina T
AU  - Nakayama I
AU  - Fountzilas C
AU  - Castillo DR
AU  - McKean M
AU  - Meric-Bernstam F
AU  - Colombo N
AU  - Smithy JW
AU  - Fayette J
AU  - Chandra S
AU  - Sternberg DW
AU  - Jin F
AU  - Sullivan K
AU  - Yueh S
AU  - Clinthorne G
AU  - Aguilo AE
AU  - Kudchadkar R
AU  - Hayashi H
PY  - 2025
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2025.2561539
UR  - https://doi.org/10.1080/14796694.2025.2561539
ER  -

APA

T, P., A, B., B, B., T, K., T, N., I, N., C, F., DR, C., M, M., F, M., N, C., JW, S., J, F., S, C., DW, S., F, J., K, S., S, Y., G, C., AE, A., R, K., & H, H. (2025). HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.. Future oncology (London, England). https://doi.org/10.1080/14796694.2025.2561539

Source records

pubmed · retrieved 2026-09-26T15:43:50.262Z